Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.

Weiss, Johanna; Bajraktari-Sylejmani, Gzona; Haefeli, Walter Emil

Weiss, Johanna; Bajraktari-Sylejmani, Gzona; Haefeli, Walter Emil.

Affiliation

Weiss J; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. Electronic address: johanna.weiss@med.uni-heidelberg.de.
Bajraktari-Sylejmani G; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Haefeli WE; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

Chem Biol Interact ; 338: 109428, 2021 Apr 01.

Article de En | MEDLINE | ID: mdl-33647240

Sujet(s)
Mots clés

COVID-19; Camostat mesylate; Drug transporters; Drug-drug interactions; GBPA; SARS-CoV-2

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Inhibiteurs de la sérine protéinase / Interactions médicamenteuses / Esters / Guanidines Type d'étude: Etiology_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Chem Biol Interact Année: 2021 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google